GLPwatch
The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).
J Diabetes Complications · 2024
Last updated 2026-05-28In a 5-year study of 4,098 people with diabetes, retinopathy—a condition affecting the eyes—occurred in 3.7% of participants. The rate was similar across four different treatments: glargine (4.0%), glimepiride (3.2%), liraglutide (3.7%), and sitagliptin (3.8%).
AI summary of the abstract below.
| Journal | J Diabetes Complications, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.18 |
| NIH percentile | 12 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143.
Verbatim abstract via PubMed 38354481 ↗